Arcus Biosciences

Founded in 2015, Arcus Biosciences is a highly productive, clinical-stage, global biopharmaceutical company with the goal of developing best-in-class molecules and combination therapies for people with cancer. Its team of scientists, physicians, advisors, and other leaders targets well-understood biological pathways where there is an opportunity to develop medicines with improved safety and efficacy. Arcus has advanced molecules from program initiation to IND filing in as short as 18 months, and moves from proof-of-concept Phase 1 to randomized Phase 2 and registrational Phase 3 studies in just a few years, guided by its vision of "Combining to Cure."